SEC Filings


All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual and financial reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to GlaxoSmithKline plc


DateFormTitle
2017-12-18 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-12-15 6-K GSK / GlaxoSmithKline plc TRANSFER OF SHARES OUT OF TREASURY (Current Report of Foreign Issuer)
2017-12-12 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-12-12 6-K GSK / GlaxoSmithKline plc GSK GAINS US APPROVAL FOR NUCALA TO TREAT EGPA (Current Report of Foreign Issuer)
2017-12-12 6-K GSK / GlaxoSmithKline plc PROMISING DATA FOR GSK2857916 AT ASH MEETING (Current Report of Foreign Issuer)
2017-12-06 6-K GSK / GlaxoSmithKline plc NEW DATA - SHINGRIX IN IMMUNE-COMPROMISED PATIENTS (Current Report of Foreign Issuer)
2017-12-01 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-12-01 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-12-01 6-K GSK / GlaxoSmithKline plc TOTAL VOTING RIGHTS (Current Report of Foreign Issuer)
2017-11-27 6-K GSK / GlaxoSmithKline plc VIIV STARTS PHASE 3 LONGACTING HIV TREATMENT STUDY (Current Report of Foreign Issuer)
2017-11-22 6-K GSK / GlaxoSmithKline plc VIIV JULUCA APPROVED IN US AS FIRST 2-DRUG REGIMEN (Current Report of Foreign Issuer)
2017-11-21 6-K GSK / GlaxoSmithKline plc GSK PUBLISHES 2018 DIVIDEND DATES (Current Report of Foreign Issuer)
2017-11-16 6-K GSK / GlaxoSmithKline plc TRELEGY ELLIPTA EU APPROVAL FOR TREATMENT OF COPD (Current Report of Foreign Issuer)
2017-11-13 6-K GSK / GlaxoSmithKline plc DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-11-09 6-K GSK / GlaxoSmithKline plc BLOCK LISTING INTERIM REVIEW (Current Report of Foreign Issuer)
2017-11-08 6-K GSK / GlaxoSmithKline plc DIRECTORATE CHANGE (Current Report of Foreign Issuer)
2017-11-08 6-K GSK / GlaxoSmithKline plc DIRECTORATE CHANGE (Current Report of Foreign Issuer)
2017-11-07 6-K GSK / GlaxoSmithKline plc US REGULATORY APPLICATION FOR MEPOLIZUMAB IN COPD (Current Report of Foreign Issuer)
2017-11-02 6-K GlaxoSmithKline BCMA RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION (Current Report of Foreign Issuer)
2017-11-01 6-K GlaxoSmithKline TOTAL VOTING RIGHTS (Current Report of Foreign Issuer)
2017-11-01 6-K GlaxoSmithKline SUPERIORITY OF ANORO ELLIPTA DEMONSTRATED FOR COPD (Current Report of Foreign Issuer)
2017-10-25 6-K GlaxoSmithKline CDC ACIP MAKES RECOMMENDATIONS FOR USE OF SHINGRIX (Current Report of Foreign Issuer)
2017-10-25 6-K GlaxoSmithKline 3RD QUARTER RESULTS (Current Report of Foreign Issuer)
2017-10-25 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-23 6-K GlaxoSmithKline GSK S SHINGRIX RECEIVES US FDA APPROVAL (Current Report of Foreign Issuer)
2017-10-21 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-21 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-16 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-16 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-16 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-16 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-16 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-16 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-13 6-K GlaxoSmithKline GSK FIRST APPROVAL OF SHINGRIX IN CANADA (Current Report of Foreign Issuer)
2017-10-13 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-13 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-13 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-11 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-10-02 6-K GlaxoSmithKline TOTAL VOTING RIGHTS (Current Report of Foreign Issuer)
2017-09-25 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-09-20 6-K GlaxoSmithKline POSITIVE IMPACT RESULTS FOR TRELEGY IN COPD (Current Report of Foreign Issuer)
2017-09-19 6-K GlaxoSmithKline TRELEGY ELLIPTA: FDA APPROVAL IN COPD RECEIVED (Current Report of Foreign Issuer)
2017-09-15 6-K GlaxoSmithKline TRELEGY ELLIPTA: POSITIVE OPINION FROM CHMP EUROPE (Current Report of Foreign Issuer)
2017-09-14 6-K GlaxoSmithKline UNANIMOUS FDA APPROVAL FOR SHINGRIX IN OVER 50S (Current Report of Foreign Issuer)
2017-09-12 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-09-12 6-K GlaxoSmithKline GSK: PHASE III RESULTS ON MEPO IN COPD IN NEJM (Current Report of Foreign Issuer)
2017-09-11 6-K GlaxoSmithKline GSK ANNOUNCE POSITIVE RESULTS FROM SLS LUNG STUDY (Current Report of Foreign Issuer)
2017-09-06 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
2017-09-01 6-K GlaxoSmithKline TOTAL VOTING RIGHTS (Current Report of Foreign Issuer)
2017-08-10 6-K GlaxoSmithKline DIRECTOR/PDMR SHAREHOLDING (Current Report of Foreign Issuer)
CUSIP: 37733W105